Prosecution Insights
Prosecution Insights
13 pending office actions • 4 clients • 12 examiners • 7 art units • 0 of 13 (0%) have an AI response strategy ready • 20 patents granted in the last 365 days
Based on the USPTO statutory response window for each pending office action. 9 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 9 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 3 (23%) |
| §102 only | 4 (31%) |
| §112 only | 1 (8%) |
| Double-patenting only | 1 (8%) |
| Double-patenting + other | 1 (8%) |
| Multi-statute (no §101) | 2 (15%) |
| No statute on record | 1 (8%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| LADD, CAROLYN LOUISE | 2 | 57.0% | +47.9% |
| CESARE, JOSEPH DAVID | 1 | — | — |
| BELL, SARA ELIZABETH | 1 | 68.5% | +39.7% |
| CHICKS, ASHLI ARIANA | 1 | 63.2% | +45.9% |
| HUI, SAN MING R | 1 | 59.3% | +19.9% |
| ANDERSON, REBECCA L | 1 | 73.3% | +23.8% |
| ABDALHAMEED, MANAHIL MIRGHANI ALI | 1 | 50.4% | +40.1% |
| HEITMEIER, KENDALL NICOLE | 1 | 63.9% | +41.7% |
| HIRAKIS, SOPHIA P | 1 | 52.2% | +73.3% |
| GAUGER, PAUL RANDALL | 1 | 57.9% | -8.8% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17801709 | POTENT AND SELECTIVE DEGRADERS OF ALK | HEITMEIER, KENDALL NICOLE | 182d overdue |
| 17773992 | SELECTIVE DUAL HISTONE DEACETYLASE 6/8 (HDAC6/8) DEGRADERS AND METHODS OF USE THEREOF | HIRAKIS, SOPHIA P | 49d overdue |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17801709 | POTENT AND SELECTIVE DEGRADERS OF ALK | HEITMEIER, KENDALL NICOLE | 182d overdue |
| 17773992 | SELECTIVE DUAL HISTONE DEACETYLASE 6/8 (HDAC6/8) DEGRADERS AND METHODS OF USE THEREOF | HIRAKIS, SOPHIA P | 49d overdue |
| 18215286 | INHIBITORS OF TRIM33 AND METHODS OF USE | ANDERSON, REBECCA L | 42d overdue |
| 17284250 | DEGRADERS OF WILD-TYPE AND MUTANT FORMS OF LRRK2 | LADD, CAROLYN LOUISE | 25d overdue |
| 18033872 | COMPOUNDS FOR TARGETED PROTEIN DEGRADATION OF KINASES | ABDALHAMEED, MANAHIL MIRGHANI ALI | 22d |
| 18281861 | INHIBITORS OF THE PEPTIDYL-PROLYL CIS/TRANS ISOMERASE (PIN1) AND USES THEREOF | CHICKS, ASHLI ARIANA | 54d |
| 18567873 | SMALL MOLECULE INHIBITORS OF KRAS G12D MUTANT | BELL, SARA ELIZABETH | — |
| 18280877 | EP300 DEGRADER AND USES THEREOF IN NEUROBLASTOMA | HUI, SAN MING R | — |
| Client (Assignee) | Pending OAs |
|---|---|
| DANA-FARBER CANCER INSTITUTE, INC. | 10 |
| Weizmann Institute of Science | 1 |
| Yeda Research And Devlopment Co. Ltd. | 1 |
| KIST | 1 |
| Art Unit | Apps |
|---|---|
| 1622 | 3 |
| 1626 | 2 |
| 1627 | 2 |
| 1621 | 2 |
| 1625 | 1 |
| 1623 | 1 |
| 1629 | 1 |
| App # | Title | Client | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|---|
| 18572972 | INHIBITORS OF THE PEPTIDYL-PROLYL CIS/TRANS ISOMERASE (PIN1), COMBINATIONS AND USES THEREOF | Yeda Research And Development Co. Ltd. | CESARE, JOSEPH DAVID | §102§112DP | Non-Final OA | — | Pending | Dec 21, 2023 | |
| 18567873 | SMALL MOLECULE INHIBITORS OF KRAS G12D MUTANT | DANA-FARBER CANCER INSTITUTE, INC. | BELL, SARA ELIZABETH | 1625 | §102 | Final Rejection | — | Pending | Dec 07, 2023 |
| 18281861 | INHIBITORS OF THE PEPTIDYL-PROLYL CIS/TRANS ISOMERASE (PIN1) AND USES THEREOF | Yeda Research And Devlopment Co. Ltd. | CHICKS, ASHLI ARIANA | 1626 | §102Other | Non-Final OA | 54d | Pending | Sep 13, 2023 |
| 18280877 | EP300 DEGRADER AND USES THEREOF IN NEUROBLASTOMA | DANA-FARBER CANCER INSTITUTE, INC. | HUI, SAN MING R | 1627 | §112 | Non-Final OA | — | Pending | Sep 07, 2023 |
| 18215286 | INHIBITORS OF TRIM33 AND METHODS OF USE | DANA-FARBER CANCER INSTITUTE, INC. | ANDERSON, REBECCA L | 1626 | §102 | Final Rejection | 42d overdue | Pending | Jun 28, 2023 |
| 18033872 | COMPOUNDS FOR TARGETED PROTEIN DEGRADATION OF KINASES | Korea Institute Of Science And Technology (Kist) | ABDALHAMEED, MANAHIL MIRGHANI ALI | 1622 | §103 | Non-Final OA | 22d | Pending | Apr 26, 2023 |
| 17801709 | POTENT AND SELECTIVE DEGRADERS OF ALK | DANA-FARBER CANCER INSTITUTE, INC. | HEITMEIER, KENDALL NICOLE | 1621 | §102§103§112 | Final Rejection | 182d overdue | Pending | Aug 23, 2022 |
| 17773992 | SELECTIVE DUAL HISTONE DEACETYLASE 6/8 (HDAC6/8) DEGRADERS AND METHODS OF USE THEREOF | DANA-FARBER CANCER INSTITUTE, INC. | HIRAKIS, SOPHIA P | 1623 | §103§112 | Final Rejection | 49d overdue | Pending | May 03, 2022 |
| 17774002 | SELECTIVE HISTONE DEACETYLASE (HDAC) DEGRADERS AND METHODS OF USE THEREOF | DANA-FARBER CANCER INSTITUTE, INC. | GAUGER, PAUL RANDALL | 1629 | §103 | Final Rejection | 31d overdue | Pending | May 03, 2022 |
| 17621057 | HCK DEGRADERS AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. | LADD, CAROLYN LOUISE | 1622 | DP | Final Rejection | — | Pending | Dec 20, 2021 |
| 17419965 | SMALL MOLECULE DEGRADERS OF FKBP12 VIA RECRUITMENT OF VON HIPPEL-LINDAU E3 UBIQUITIN LIGASE (VHL) E3 UBIQUITIN LIGASE, AND USES IN dTAG SYSTEMS | DANA-FARBER CANCER INSTITUTE, INC. | YOO, SUN JAE | 1621 | — | Final Rejection | 15d overdue | Pending | Jun 30, 2021 |
| 17284250 | DEGRADERS OF WILD-TYPE AND MUTANT FORMS OF LRRK2 | DANA-FARBER CANCER INSTITUTE, INC. | LADD, CAROLYN LOUISE | 1622 | §103Other | Non-Final OA | 25d overdue | Pending | Apr 09, 2021 |
| 17265139 | HISTONE DEMETHYLASE 5 INHIBITORS AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. | PECKHAM, RICHARD GRANT | 1627 | §102 | Non-Final OA | 42d overdue | Pending | Feb 01, 2021 |
IP Author helps law firms respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial